基于遗传与临床因素开发并验证预测亚洲非酒精性脂肪性肝病患者脂肪性肝炎风险的评分系统
该研究基于韩国Boramae注册库453例经活检证实的NAFLD患者,利用PNPLA3和TM6SF2基因多态性及临床因素构建NASH预测评分(NASH PT),在发现队列中AUROC为0.859,验证队列中AUROC为0.787,显著优于NASH评分(0.729)。NASH PT评分有助于识别伴或不伴糖尿病的NAFLD患者中的NASH高风险人群。
要点
- NASH PT评分基于PNPLA3和TM6SF2基因型、糖尿病状态、胰岛素抵抗、AST和hs-CRP水平构建。
- 验证队列中NASH PT评分识别NASH的AUROC为0.787,显著高于NASH评分的0.729。
- 在糖尿病患者中,NASH PT评分<-0.785对NASH的阴性预测值达0.905。
核心结论
- 基于PNPLA3和TM6SF2多态性及临床因素的NASH PT评分可识别伴或不伴糖尿病的NAFLD患者中的NASH,验证队列AUROC为0.787。
研究设计与样本
- 研究收集韩国Boramae注册库453例经活检证实的NAFLD患者数据,2014年2月至2016年3月入组者归为发现队列(n=302),之后入组者归为验证队列(n=151)。
主要发现
- NASH PT评分在发现队列中识别NASH的AUROC为0.859(95% CI, 0.817-0.901)。
- 在验证队列中,NASH PT评分识别NASH的AUROC为0.787(95% CI, 0.715-0.860),显著高于NASH评分的AUROC 0.729(95% CI, 0.647-0.812;P = .007)。
- NASH PT评分在伴糖尿病患者中检测NASH的AUROC为0.835(95% CI, 0.776-0.895),在不伴糖尿病患者中为0.809(95% CI, 0.757-0.861)。
- NASH PT评分<-0.785对伴糖尿病NAFLD患者NASH的阴性预测值为0.905。
临床怎么用
- NASH PT评分可能帮助临床医生更好地识别有NASH风险的NAFLD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are no biomarkers of nonalcoholic steatohepatitis (NASH) that are ready for routine clinical use. We investigated whether an analysis of PNPLA3 and TM6SF2 genotypes (rs738409 and rs58542926) can be used to identify patients with nonalcoholic fatty liver disease (NAFLD), with and without diabetes, who also have NASH. METHODS: We collected data from the Boramae registry in Korea on 453 patients with biopsy-proven NAFLD with sufficient clinical data for calculating scores. Patients enrolled from February 2014 through March 2016 were assigned to cohort 1 (n = 302; discovery cohort) and patients enrolled thereafter were assigned to cohort 2 (n = 151; validation cohort). DNA samples were obtained from all participants and analyzed for the PNPLA3 rs738409 C>G, TM6SF2 rs58542926 C>T, SREBF2 rs133291 C>T, MBOAT7-TMC4 rs641738 C>T, and HSD17B13 rs72613567 adenine insertion (A-INS) polymorphisms. We used multivariable logistic regression analyses with stepwise backward selection to build a model to determine patients' risk for NASH (NASH PT) using the genotype and clinical data from cohort 1 and tested its accuracy in cohort 2. We used the receiver operating characteristic (ROC) curve to compare the diagnostic performances of the NASH PT and the NASH scoring systems. RESULTS: We developed a NASH PT scoring system based on PNPLA3 and TM6SF2 genotypes, diabetes status, insulin resistance, and levels of aspartate aminotransferase and high-sensitivity C-reactive protein. NASH PT scores identified patients with NASH with an area under the ROC (AUROC) of 0.859 (95% CI, 0.817-0.901) in cohort 1. In cohort 2, NASH PT scores identified patients with NASH with an AUROC of 0.787 (95% CI, 0.715-0.860), which was significantly higher than the AUROC of the NASH score (AUROC, 0.729; 95% CI, 0.647-0.812; P = .007). The AUROC of the NASH PT score for detecting NASH in patients with NAFLD with diabetes was 0.835 (95% CI, 0.776-0.895) and in patients without diabetes was 0.809 (95% CI, 0.757-0.861). The negative predictive value of the NASH PT score <-0.785 for NASH in patients with NAFLD with diabetes reached 0.905. CONCLUSIONS: We developed a scoring system, based on polymorphisms in PNPLA3 and TM6SF2 and clinical factors that identifies patients with NAFLD, with or without diabetes, who have NASH, with an AUROC value of 0.787. This system might help clinicians better identify NAFLD patients at risk for NASH.
引用
- Koo BK, Joo SK, Kim D, et al. Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32062042. doi:10.1016/j.cgh.2020.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。